Suppr超能文献

氨苄西林-舒巴坦与头孢西丁在大鼠腹腔脓肿模型中治疗大肠杆菌感染的疗效比较

Efficacy of ampicillin-sulbactam versus that of cefoxitin for treatment of Escherichia coli infections in a rat intra-abdominal abscess model.

作者信息

Rice L B, Carias L L, Shlaes D M

机构信息

Medicine Service, Department of Veterans' Affairs Medical Center, Cleveland, Ohio.

出版信息

Antimicrob Agents Chemother. 1993 Mar;37(3):610-2. doi: 10.1128/AAC.37.3.610.

Abstract

We examined the efficacy of ampicillin-sulbactam (2:1) and cefoxitin in the treatment of infections caused by Escherichia coli strains exhibiting increasing levels of beta-lactamase-mediated resistance to ampicillin-sulbactam in the rat intra-abdominal abscess model. Cefoxitin was superior to ampicillin-sulbactam in the treatment of infections caused by all strains. Treatment with ampicillin-sulbactam resulted in a statistically significant decrease in CFU per gram of abscess in comparison with treatment with ampicillin alone for both the moderately resistant and the resistant strains, with an inverse correlation between the MIC and the absolute decrease in CFU per gram of abscess.

摘要

我们在大鼠腹腔脓肿模型中研究了氨苄西林-舒巴坦(2:1)和头孢西丁对表现出对氨苄西林-舒巴坦的β-内酰胺酶介导耐药性不断增加的大肠杆菌菌株所致感染的治疗效果。在治疗所有菌株引起的感染方面,头孢西丁优于氨苄西林-舒巴坦。对于中度耐药和耐药菌株,与单独使用氨苄西林治疗相比,用氨苄西林-舒巴坦治疗导致每克脓肿中的菌落形成单位(CFU)有统计学意义的下降,最低抑菌浓度(MIC)与每克脓肿中CFU的绝对下降之间呈负相关。

相似文献

本文引用的文献

6
Amoxycillin/clavulanate resistant Escherichia coli.阿莫西林/克拉维酸耐药的大肠杆菌
Lancet. 1988 Feb 6;1(8580):304-5. doi: 10.1016/s0140-6736(88)90391-1.
7
Resistance to beta-lactam/clavulanate.对β-内酰胺/克拉维酸的耐药性。
Lancet. 1987 Dec 19;2(8573):1473. doi: 10.1016/s0140-6736(87)91180-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验